STOCK TITAN

Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced that CEO Dr. Tiago Reis Marques will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation is scheduled for September 12, 2022, at 7:00 AM ET. Attendees can request virtual one-on-one meetings through H.C. Wainwright. A pre-recorded presentation will also be available on the Company’s website. Pasithea focuses on researching treatments for psychiatric and neurological disorders, including IV ketamine infusions for patients in clinical and home settings.

Positive
  • None.
Negative
  • None.

MIAMI BEACH, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its Chief Executive Officer, Dr. Tiago Reis Marques, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference, being held from September 12-14, 2022 in New York, as follows:

Date:  Monday, September 12, 2022
Time:  7:00AM ET

During the conference Pasithea will be participating in virtual 1x1 meetings that can be requested via H.C. Wainwright.

A pre-recorded presentation will be made will be accessible via the Company’s website at ir.pasithea.com.

About Pasithea Therapeutics Corp. 
Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings. 

Pasithea Therapeutics Corp. Company Contact 
Dr. Tiago Reis Marques 
Chief Executive Officer 
E: tiago@pasithea.com 

Pasithea Therapeutics Corp. Investor Relations 
Lisa M. Wilson 
In-Site Communications, Inc. 
T: 212-452-2793 
E: lwilson@insitecony.com 


FAQ

When will Pasithea Therapeutics present at the H.C. Wainwright Conference?

Pasithea Therapeutics will present on September 12, 2022, at 7:00 AM ET.

How can I watch Pasithea's pre-recorded presentation?

The pre-recorded presentation will be accessible on the Company's website at ir.pasithea.com.

What is the focus of Pasithea Therapeutics?

Pasithea Therapeutics focuses on developing treatments for psychiatric and neurological disorders.

What stock symbols are associated with Pasithea Therapeutics?

Pasithea Therapeutics trades under the stock symbols KTTA and KTTAW.

Will Pasithea have one-on-one meetings during the conference?

Yes, Pasithea will participate in virtual one-on-one meetings that can be requested via H.C. Wainwright.

Pasithea Therapeutics Corp.

NASDAQ:KTTA

KTTA Rankings

KTTA Latest News

KTTA Stock Data

3.27M
1.02M
23.12%
2.87%
1.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
VENICE